Microbiome in IEI, Much More Than Probiotics

“We came up with the idea of testing a ketogenic diet… which in mice, it’s basically a lot of Crisco… giving a keto diet to mice with CGD… led to a decreased susceptibility to colitis.” —Dr. Emilia Liana Falcone

The microbiome isn’t something sitting on the sidelines. It’s part of the immune system, interacting with the barrier, shaping responses, and, in IEI, reflecting the underlying defect.

On this episode, Dr. Mariam Hanna is joined by Dr. Emilia Liana Falcone, physician-scientist and director of the Microbiome and Mucosal Defense Research Unit at the Montreal Clinical Research Institute, to walk through how these host–microbe interactions drive disease. From early-life immune programming to microbial signals that activate inflammatory pathways, this is a shift from association to mechanism. And a step toward therapies that target both sides of the equation.

Key Points:

• The microbiome reflects the underlying immune defect in IEI
• Focus on what microbes are doing, not just which ones are present
• Microbiome changes both result from—and contribute to—disease
• Early life is a critical window where these interactions are set
• Loss of protective microbial functions matters more than specific bacteria
• Microbial signals can directly drive inflammation (including inflammasome activation)
• Future treatments will likely combine immune therapy with microbiome-targeted approaches

This is not about adding a probiotic.

It’s about understanding how immune defects reshape the microbial environment, and how that environment feeds back into disease.

Get that interaction right, and you’re not just managing symptoms.

You’re changing the system driving them.

Visit the Canadian Society of Allergy and Clinical Immunology

Find an allergist using our helpful tool

Find Dr. Hanna on X, previously Twitter, @PedsAllergyDoc or CSACI @CSACI_ca

The Allergist is produced for CSACI by PodCraft Productions